Unknown Author
January 23, 2026
Sidley Represents Savillex Corporation, a Portfolio Company of Thompson Street Capital Partners, in Acquisition of Onfab From Foresight Group

1 min
AI-made summary
- Sidley advised Savillex Corporation, a portfolio company of Thompson Street Capital Partners, on its acquisition of ONFAB
- ONFAB specializes in producing custom, flexible single-use containment solutions for small molecule and biopharmaceutical drug manufacturing
- The Sidley legal team was led by partners Robert Darwin and Brent Steele, with support from professionals across private equity, finance, real estate, employment, global arbitration, trade, advocacy, and tax practice areas.
Sidley advised Savillex Corporation, a portfolio company of private equity firm Thompson Street Capital Partners, in its strategic acquisition of ONFAB. ONFAB produces bespoke, flexible single-use containment solutions used in small molecule and biopharmaceutical drug manufacturing, enabling pharmaceutical sponsors, suppliers, and researchers to manufacture drugs safely.
The Sidley team was led by Private Equity partner Robert Darwin and M&A partner Brent Steele and supported by managing associates Cindy Yuan, Kimberley Vanderspar, and Thomas E. Johnson, associates Jessica Edwards, Samuel Tee, and Henna Thakur (Private Equity); partners James Crooks and Annie Wallis, senior managing associate Chloe Smith, managing associate Christian Wyse, and associates Esther Crang and Angela B. Gallagher (Finance); partner Jade Williams-Adedeji and senior managing associate Jack Mayall (Real Estate); partner Peter McCorkell, senior managing associate Alex Down and associate Maeve Gillespie (Employment); counsel Christopher Lock (Global Arbitration, Trade and Advocacy); and partner Jason Menzies and associate Fraser Tudor (Tax).~~Sidley advised Savillex Corporation, a portfolio company of private equity firm Thompson Street Capital Partners, in its strategic acquisition of ONFAB. ONFAB produces bespoke, flexible single-use containment solutions used in small molecule and biopharmaceutical drug manufacturing, enabling pharmaceutical sponsors, suppliers, and researchers to manufacture drugs safely.
The Sidley team was led by Private Equity partner Robert Darwin and M&A partner Brent Steele and supported by managing associates Cindy Yuan, Kimberley Vanderspar, and Thomas E. Johnson, associates Jessica Edwards, Samuel Tee, and Henna Thakur (Private Equity); partners James Crooks and Annie Wallis, senior managing associate Chloe Smith, managing associate Christian Wyse, and associates Esther Crang and Angela B. Gallagher (Finance); partner Jade Williams-Adedeji and senior managing associate Jack Mayall (Real Estate); partner Peter McCorkell, senior managing associate Alex Down and associate Maeve Gillespie (Employment); counsel Christopher Lock (Global Arbitration, Trade and Advocacy); and partner Jason Menzies and associate Fraser Tudor (Tax).
Article Author
Unknown Author
The Sponsor
